Skip to main content

Table 3 Univariate and Multivariate Cox regression analysis for all cases of Cohort 1 (n = 758)

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

  Univariate Multivariate
OS PFS OS PFS
HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value
Histology Astro grade II 0.91 0.518–1.594 0.74 1.23 0.788–1.906 0.37 0.58 0.323–1.027 0.06 0.92 0.585–1.461 0.74
Astro grade III 2.14 1.410–3.245 0.0003 1.85 1.291–2.638 0.0008 1.02 0.658–1.566 0.95 0.99 0.682–1.447 0.97
GBM 4.02 2.860–5.635 <0.0001 3.73 2.801–4.974 <0.0001 1.24 0.842–1.813 0.28 1.43 1.024–1.989 0.04
Oligo grade II 0.25 0.127–0.504 <0.0001 0.48 0.313–0.749 0.001 0.42 0.207–0.846 0.02 0.6 0.381–0.928 0.02
Oligo grade III Ref Ref Ref Ref
Molecular group* Group A 0.04 0.023–0.073 <0.0001 0.1 0.070–0.142 <0.0001 0.09 0.048–0.180 <0.0001 0.19 0.124–0.296 <0.0001
Group B 0.12 0.079–0.184 <0.0001 0.18 0.126–0.242 <0.0001 0.29 0.172–0.480 <0.0001 0.33 0.218–0.492 <0.0001
Group C 0.58 0.454–0.735 <0.0001 0.62 0.499–0.773 <0.0001 0.71 0.545–0.919 0.01 0.7 0.553–0.888 0.003
Group D Ref Ref Ref Ref
Location Cerebrum 0.79 0.482–1.305 0.36 0.65 0.430–0.985 0.04 excluded by the factor selection with step-wise method 0.67 0.427–1.045 0.08
Cerebrum with frontal Involvement 0.40 0.242–0.670 0.0005 0.31 0.203–0.475 <0.0001 0.5 0.316–0.779 0.002
Other Ref Ref Ref
Age   1.048a 1.040–1.057 <0.0001 1.033a 1.027–1.040 <0.0001 1.02a 1.011–1.029 <0.0001 1.01a 1.003–1.018 0.007
Sex M Ref Ref Ref Ref
F 0.91 0.724–1.134 0.39 0.95 0.781–1.150 0.58 0.72 0.572–0.905 0.005 0.81 0.663–0.982 0.03
KPS 0.971b 0.965–0.976 <0.0001 0.98b 0.974–0.985 <0.0001 0.99b 0.983–0.997 0.008 excluded by factor selection with step-wise method
Surgery Biopsy 1.85 1.416–2.427 <0.0001 1.41 1.092–1.817 0.008 2.05 1.522–2.755 <0.0001 1.6 1.204–2.121 0.001
  Removal Ref Ref Ref Ref
Adjuvant Therapy CRT 2.02 1.132–3.601 0.02 1.78 1.110–2.868 0.02 excluded by factor selection with step-wise method excluded by factor selection with step-wise method
Chemo 0.84 0.392–1.792 0.65 0.87 0.472–1.587 0.64
RT Ref Ref
None 0.45 0.197–1.010 0.05 0.74 0.411–1.333 0.32
  1. Astro grade II diffuse astrocytoma, Astro grade III anaplastic astrocytoma, Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky Performance status, M Male, mut mutatant, Oligo grade II oligodendroglioma and oligoastrocytoma, Oligo grade III anaplastic oligodendroglioma and anaplastic oligoastrocytoma, OS overall survival, PFS progression free survival, Ref Reference, RT radiation therapy, wt wild type
  2. * Group A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated
  3. a HR is for each one year increase, b HR is for each 1 % increase